Compliance in an Outsource Manufacturing Model: What to Look For - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Compliance in an Outsource Manufacturing Model: What to Look For
The authors provide detailed lists of important checkpoints to consider when selecting an outsourcing provider.


Pharmaceutical Technology


Whether for reasons of risk management, capacity requirements, capital limitations, or lack of available human resources, pharmaceutical companies are increasingly entering into outsourcing relationships for the management of their supply chains. Outsourcing allows a company to realize the benefits of production and sales without maintaining infrastructure or making large capital investments. Although such relationships are advantageous, the pharmaceutical company entering into them retains ultimate responsibility for the quality of its compound. Therefore, careful consideration must be given in the selection and review of an outsourcing provider to ensure compliance.

A company must first determine whether outsourcing is needed. The answer can be as simple or as complex as a given supply chain and may comprise several answers. The company must make a clear-eyed evaluation of its strengths and weaknesses, its available resources, and its risk tolerance to develop an outsourcing model that is applicable to its unique situation. For companies in need of outsourcing, this article serves as a guide for selecting where outsourcing should take place.

Selecting an outsourcing provider

The factors to consider when selecting an outsouring provider and the relevant questions a company should ask include the following:
  • Capability: Does the provider have the equipment, personnel, and experience to meet my outsourcing needs? Are investments needed to close any gaps to meet this needs? Does the facility have a history in my area of interest?
  • Capacity: Will my product be fighting for share of voice with others?
  • Commitment: Is the company financially sound? Have we reviewed their annual report? What is the long-term view of the company?
  • Competition: Does the company work with our competition? Do we have guaranteed access to capacity? Are there systems in place to protect proprietary information?

The first stage in entering into outsourcing, then, is ensuring that a potential partner has the infrastructure, experience, and financial health to provide assurance that the project will succeed. It will do no good if the company has excellent systems and equipment but is ready to shut its doors because of a lost contract. Conversely, a company with a strong balance sheet may not have the right experience that would be required. More, a sponsor company and its competition may arrive at the same conclusion, and so the sponsor's information must be protected and product supply needs must be ensured. With these answers, the sponsor company can proceed with confidence to evaluating the compliance capabilities of the supplier.

Each product and process is different. Therefore, ensuring compliance in an outsourced model must take into account the specific needs of the product in the context of GMPs and other relevant regulations.

In the United States, for example, the US Food and Drug Administration expects drug, medical device, and biologics manufacturers to have an active facility and supplier audit program, even though there are no specific requirements in the regulations that show that audits of the quality systems have been conducted. Although the word audit is not included in 21 CFR Parts 210 and 211, the requirement for and responsibilities of a "quality control unit" are nonetheless elucidated. FDA currently takes a systems approach that includes the quality system, facilities and equipment, materials management, production, packaging and labeling, and laboratory controls. The elements of these systems are defined in 21 CFR 211 and in the various FDA guidances and should be included in the audit.

Audit checklists can cover all areas of production, from the receipt of raw materials to final release of product, as well as support systems and controls. Or, they can be custom made by the auditor to ensure that each term in the audit plans is specifically addressed. The following are a sample checklists an auditor might use to perform a GMP lab audit.

Quality assurance oversight

  • Does the quality assurance (QA) staff review calculations, weights, record completeness? Does it perform final approval?
  • Are procedures in approved, written documents?
  • Does the QA staff review all deviations and investigations?
  • Does the QA staff routinely review production records to ensure that procedures are followed and properly documented?
  • Is there a standard operating procedure that defines the QA department's responsibilities?


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here